Lithera Reports Positive Clinical Study Results From a Second Phase IIa Trial for LIPO-102, a Novel Treatment for Localized Fat Reduction

Published: May 05, 2010

SAN DIEGO, May 5, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. LIPO-102 was well-tolerated when administered weekly for 8 weeks into the subcutaneous abdominal fat of healthy subjects. LIPO-102 injections in the anterior abdomen produced dose- and time-related reductions in mean abdominal circumference and volume of -1.2 cm (versus -0.1 cm for placebo; p=0.048) and -183 cc (versus +24 cm for placebo; p=0.023), respectively, using 3-D photographic imaging. Consistent with the pharmacology of LIPO-102 and known changes in lipolytic sensitivity with age, younger and thinner patients demonstrated even larger mean reductions in abdominal volume and circumference (-360 cc and -2.2 cm, respectively). The effects of the optimal dose of LIPO-102 (1 mcg SX + 22 mcg FP) on abdominal circumference and volume persisted for 6 to 12 weeks post-treatment.

Back to news